<?xml version="1.0" encoding="UTF-8"?>
<document id="24608572">
	<sentence id="s1" text="One upregulated candidate named transmembrane protein 98 (TMEM98) was found to be overexpressed in 80 of 118 (67.80%) of patients with hepatocellular carcinoma.">
		<entity id="s1.e1" charOffset="58-64"
			type="GENE" text="TMEM98" ontology_id="26022"/>
		<entity id="s1.e2" charOffset="135-159"
			type="HP" text="hepatocellular carcinoma" ontology_id="HP_0001402"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="false"/>
	</sentence>
	<sentence id="s2" text="TMEM98 mRNA in tumor tissues was significantly higher than nontumor tissues of patients with hepatocellular carcinoma (P AAAA 0.0001).">
		<entity id="s2.e1" charOffset="0-6"
			type="GENE" text="TMEM98" ontology_id="26022"/>
		<entity id="s2.e2" charOffset="15-20"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s2.e3" charOffset="93-117"
			type="HP" text="hepatocellular carcinoma" ontology_id="HP_0001402"/>
		<pair id="s2.p1" e1="s2.e1"
		    e2="s2.e3" pgr="false"/>
		<pair id="s2.p2" e1="s2.e1"
		    e2="s2.e2" pgr="false"/>
	</sentence>
	<sentence id="s3" text="Upregulation of TMEM98 was significantly correlated with advanced tumor stage (P = 0.048), high incidence of early tumor recurrence (P = 0.005), poor overall survival (P = 0.029), and poor disease-free survival (P = 0.011) of patients with hepatocellular carcinoma after hepatectomy.">
		<entity id="s3.e1" charOffset="16-22"
			type="GENE" text="TMEM98" ontology_id="26022"/>
		<entity id="s3.e2" charOffset="66-71"
			type="HP" text="tumor" ontology_id="HP_0002664"/>
		<entity id="s3.e3" charOffset="240-264"
			type="HP" text="hepatocellular carcinoma" ontology_id="HP_0001402"/>
		<pair id="s3.p1" e1="s3.e1"
		    e2="s3.e3" pgr="false"/>
		<pair id="s3.p2" e1="s3.e1"
		    e2="s3.e2" pgr="false"/>
	</sentence>
	<sentence id="s4" text="Importantly, upregulation of TMEM98 mRNA in patients with hepatocellular carcinoma who received transarterial chemoembolization (TACE) treatment was significantly higher than in patients without TACE treatment (P = 0.046).">
		<entity id="s4.e1" charOffset="29-35"
			type="GENE" text="TMEM98" ontology_id="26022"/>
		<entity id="s4.e2" charOffset="58-82"
			type="HP" text="hepatocellular carcinoma" ontology_id="HP_0001402"/>
		<entity id="s4.e3" charOffset="129-133"
			type="GENE" text="TACE" ontology_id="6868"/>
		<pair id="s4.p1" e1="s4.e1"
		    e2="s4.e2" pgr="false"/>
		<pair id="s4.p2" e1="s4.e2"
		    e2="s4.e3" pgr="false"/>
	</sentence>
	<sentence id="s5" text="In vitro and in vivo studies showed that suppression of TMEM98 in chemoresistant hepatocellular carcinoma cells restored their chemosensitivity, while forced overexpression of TMEM98 enhanced their chemoresistance.">
		<entity id="s5.e1" charOffset="56-62"
			type="GENE" text="TMEM98" ontology_id="26022"/>
		<entity id="s5.e2" charOffset="81-105"
			type="HP" text="hepatocellular carcinoma" ontology_id="HP_0001402"/>
		<pair id="s5.p1" e1="s5.e1"
		    e2="s5.e2" pgr="false"/>
	</sentence>
	<sentence id="s6" text="The mechanism of TMEM98 in conferring chemoresistance of hepatocellular carcinoma might be possibly through activation of the AKT pathway and deactivation of p53.">
		<entity id="s6.e1" charOffset="17-23"
			type="GENE" text="TMEM98" ontology_id="26022"/>
		<entity id="s6.e2" charOffset="57-81"
			type="HP" text="hepatocellular carcinoma" ontology_id="HP_0001402"/>
		<entity id="s6.e3" charOffset="126-129"
			type="GENE" text="AKT" ontology_id="207"/>
		<pair id="s6.p1" e1="s6.e1"
		    e2="s6.e2" pgr="false"/>
		<pair id="s6.p2" e1="s6.e2"
		    e2="s6.e3" pgr="false"/>
	</sentence>
</document>
